Last reviewed · How we verify
Pegylated liposomal doxorubicin hydrochloride
Pegylated liposomal doxorubicin hydrochloride is a Anthracycline chemotherapy (liposomal formulation) Small molecule drug developed by M.D. Anderson Cancer Center. It is currently FDA-approved for Metastatic ovarian cancer, AIDS-related Kaposi sarcoma, Multiple myeloma (in combination with bortezomib). Also known as: Caelyx, Doxil, liposomal doxorubicin, doxorubicin hydrochloride.
Pegylated liposomal doxorubicin delivers the chemotherapy agent doxorubicin encapsulated in liposomes coated with polyethylene glycol, which intercalates into DNA and inhibits topoisomerase II while reducing cardiotoxicity through prolonged circulation and selective tumor accumulation.
Pegylated liposomal doxorubicin delivers the chemotherapy agent doxorubicin encapsulated in liposomes coated with polyethylene glycol, which intercalates into DNA and inhibits topoisomerase II while reducing cardiotoxicity through prolonged circulation and selective tumor accumulation. Used for Metastatic ovarian cancer, AIDS-related Kaposi sarcoma, Multiple myeloma (in combination with bortezomib).
At a glance
| Generic name | Pegylated liposomal doxorubicin hydrochloride |
|---|---|
| Also known as | Caelyx, Doxil, liposomal doxorubicin, doxorubicin hydrochloride, liposomal doxorubicin hydrochloride |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Anthracycline chemotherapy (liposomal formulation) |
| Target | Topoisomerase II, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Doxorubicin is a topoisomerase II inhibitor and DNA intercalating agent that generates reactive oxygen species and causes DNA damage, leading to apoptosis in cancer cells. The pegylated liposomal formulation encapsulates doxorubicin to extend its half-life, reduce systemic exposure to healthy tissues (particularly the heart), and preferentially accumulate in tumors through the enhanced permeability and retention (EPR) effect, thereby improving the therapeutic index.
Approved indications
- Metastatic ovarian cancer
- AIDS-related Kaposi sarcoma
- Multiple myeloma (in combination with bortezomib)
- Breast cancer
Common side effects
- Palmar-plantar erythrodysesthesia (hand-foot syndrome)
- Nausea and vomiting
- Stomatitis
- Myelosuppression (neutropenia)
- Alopecia
- Cardiotoxicity
- Infusion reactions
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (PHASE1)
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (PHASE1)
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated liposomal doxorubicin hydrochloride CI brief — competitive landscape report
- Pegylated liposomal doxorubicin hydrochloride updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI
Frequently asked questions about Pegylated liposomal doxorubicin hydrochloride
What is Pegylated liposomal doxorubicin hydrochloride?
How does Pegylated liposomal doxorubicin hydrochloride work?
What is Pegylated liposomal doxorubicin hydrochloride used for?
Who makes Pegylated liposomal doxorubicin hydrochloride?
Is Pegylated liposomal doxorubicin hydrochloride also known as anything else?
What drug class is Pegylated liposomal doxorubicin hydrochloride in?
What development phase is Pegylated liposomal doxorubicin hydrochloride in?
What are the side effects of Pegylated liposomal doxorubicin hydrochloride?
What does Pegylated liposomal doxorubicin hydrochloride target?
Related
- Drug class: All Anthracycline chemotherapy (liposomal formulation) drugs
- Target: All drugs targeting Topoisomerase II, DNA
- Manufacturer: M.D. Anderson Cancer Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic ovarian cancer
- Indication: Drugs for AIDS-related Kaposi sarcoma
- Indication: Drugs for Multiple myeloma (in combination with bortezomib)
- Also known as: Caelyx, Doxil, liposomal doxorubicin, doxorubicin hydrochloride, liposomal doxorubicin hydrochloride
- Compare: Pegylated liposomal doxorubicin hydrochloride vs similar drugs
- Pricing: Pegylated liposomal doxorubicin hydrochloride cost, discount & access